Zegerid OTC hits retail
This article was originally published in The Tan Sheet
Executive SummaryMerck's Schering-Plough HealthCare Products begins marketing the first dual-ingredient OTC proton pump inhibitor April 1. Zegerid OTC (omeprazole 20 mg/sodium bicarbonate 1100 mg), licensed from Santarus, is available nationwide, Whitehouse Station, N.J.-based Merck said. In marketing materials, the firm plays up the PPI's unique formulation and lack of enteric coating due to the sodium bicarbonate's buffering function. Although Zegerid OTC features the tagline, "Discover the Difference," its Web site, 1www.ZegeridOTC.com, does not draw comparisons to PPI competition, including Prilosec OTC (omeprazole 20 mg) and Prevacid 24HR (lansoprazole 15 mg). Instead, Merck cites the advantages of Zegerid OTC over H2 blockers and antacids for relieving frequent heartburn
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.